US shares of Novo Nordisk gain after 'encouraging' early Wegovy pill prescription data

U.S.-listed shares of Danish drugmaker Novo Nordisk NOVOb.CO, NVO.N rise 7.8% to a near four-month high of $61.60, snapping a three-day losing streak

Stock set for its best day in nearly a year, if gains hold

Novo's Wegovy pill made an " encouraging " start in the U.S., with about 3,071 prescriptions in first four days after its launch on January 5, according to IQVIA data shared by analysts

Analysts say early uptake looks strong, but they want several weeks of data to judge how well Novo can use its first‑to‑market advantage against Lilly LLY.N

Separately, UK's health regulator approved a higher 7.2 mg weekly dose of Novo's Wegovy for obesity patients

Novo is still awaiting a UK decision on its easier‑to‑take pill version of the weight‑loss drug

*Novo's Denmark-listed shares closed at 6.5% on Friday

NVO fell ~42% in 2025